Drugmaker AbbVie expects Humira volume erosion to worsen
-AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.
He said data showed patients were also moving to other drugs such as AbbVie's newer immunology treatments Skyrizi and Rinvoq. "There seems to be a lot of concern around the impact of Humira biosimilars. That seemed to be a focus on the call with most of the questions centering around this," BMO Capital Markets analyst Evan Seigerman said, adding that Cigna's plans could hit AbbVie's Humira volume this year.
The company earlier on Friday raised its annual adjusted profit forecast to between $11.13 and $11.33 per share, compared with $10.97 to $11.17 estimated earlier. It also beat first-quarter profit estimates on strong sales of Skyrizi and cancer drug Imbruvica. Skyrizi sales of $2.01 billion beat estimates of $1.94 billion, while Rinvoq's $1.09 billion came in slightly higher than expectations of $1.06 billion.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Boehringer to lay off salespeople as Humira biosimilar sales lagBoehringer to lay off salespeople as Humira biosimilar sales lag
Read more »
Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and ColgateJim Cramer offers his take on companies outside the CNBC Investing Club’s portfolio.
Read more »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysBased on results from trials in people with sleep apnea, the company said it plans to submit the material to the US Food and Drug Administration to potentially expand the use of Zepbound for obstru…
Read more »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysThe company said it plans to submit the material to the FDA to potentially expand the use of Zepbound for obstructive sleep apnea.
Read more »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysThe company said it plans to submit the material to the FDA to potentially expand the use of Zepbound for obstructive sleep apnea.
Read more »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysZepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday.
Read more »